{"id":"82c0179fd940","type":"article","url":"https://hartvaat.nl/2026/09/01/cardiorenale-bescherming-door-sglt2-remmers-glp-1-agonisten-en-mra-s-bij-type-1-/","title":"Cardiorenale bescherming door SGLT2-remmers, GLP-1-agonisten en MRA's bij type 1-diabetes","title_en":"Emerging Evidence for Cardiorenal Protection with Sodium-Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabetes.","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog","internist"],"tags":[],"journal":"Endocrinology and metabolism clinics of North America","doi":"10.1016/j.ecl.2026.04.007","source_url":"https://doi.org/10.1016/j.ecl.2026.04.007","authors":["Stuti Fernandes","Barbara Hettinger","Lynn Ang","Rodica Pop-Busui"],"significance":5,"published":"2026-08-07","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-farmacologie/","https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/"],"congress":"","summary_en":"This narrative review synthesizes current evidence on the cardiorenal benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists in patients with type 1 diabetes. While these drug classes have fundamentally transformed cardiovascular and renal care in type 2 diabetes, robust long-term outcome data in type 1 diabetes remain limited. Clinicians should consider these agents on a case-by-case basis for cardiorenal risk reduction, pending further dedicated trials to establish definitive safety and efficacy profiles in this population.","created":"2026-08-01T00:57:48Z","updated":"2026-08-10T10:36:41Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze overzichtsstudie vat de huidige bewijslast samen voor de cardiorenale effecten van SGLT2-remmers, GLP-1-agonisten en mineralocorticoïde-receptorantagonisten bij patiënten met type 1-diabetes. Hoewel deze middelen bij type 2-diabetes de standaardzorg hebben getransformeerd, blijft de langetermijnveiligheid en effectiviteit bij type 1-diabetes nog onvoldoende onderzocht. Voor de klinische praktijk betekent dit dat deze therapieën momenteel vooral in het kader van individuele risicobeoordeling en specialistisch overleg overwogen kunnen worden, met de nadruk op het verzamelen van meer langetermijndata.","abstract_original":"Sodium-glucose cotransporter inhibitors, glucagon-like peptide 1 receptor agonists and mineralocorticoid receptor blockers have revolutionized type 2 diabetes and by providing substantial cardiovascular and renal protection in this. This article summarizes the data for these newer agents in type 1 diabetes (T1D). Here we also emphasize the need for more long-term studies of these agents in T1D to assess their impact on cardiovascular risk."}